Recombinant Biotinylated Human PD-L1 / B7-H1 (recommended for biopanning), Avi Tag (Avitag™), His Tag 25µg

Background
Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

Source
Recombinant Biotinylated Human PD-L1, Avitag,His Tag (PD1-H82E5) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Arg 238 (Accession # NP_054862.1).
Predicted N-terminus: Phe 19

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 27.8 kDa. The protein migrates as 33-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Application
PD1-H82E5 works best for experiments that test the binding between PD-L1 and candidate antibodies, such as biopanning and other relevant assays.
This product is NOT suitable for testing PD1-PDL1 binding. For this type of application, we strongly recommend you to choose PD1-H82F3 as an alternative.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma
Zhao, He, Zhu et al
Br J Cancer (2022)
(2) "Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect
Liu, Zhang, Liu et al
Br J Cancer (2022)
(3) "Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study
de la Cruz-Merino, Gion, Cruz et al
BMC Cancer (2022) 22 (1), 1258
Showing 1-3 of 22904 papers.

Citations

(1) "A small-sized protein binder specific for human PD-1 effectively suppresses the tumor growth in tumor mouse model"
Authors: Son S, et al
Journal: J Drug Target 2019
Application: ELISA
(2) "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors"
Authors: Ganesan A, et al
Journal: Sci Rep 2019
Application: ELISA
(3) "Anti-pd-1 antibodies and methods of use thereof"
Authors: Yasmina Noubia Abdiche, et al.
Journal: US20160159905A1 2016
Application: Flow Cytometry